ES2096843T3 - Piridinas sustituidas como inhibidores de reductosa hmg-coa. - Google Patents

Piridinas sustituidas como inhibidores de reductosa hmg-coa.

Info

Publication number
ES2096843T3
ES2096843T3 ES93120057T ES93120057T ES2096843T3 ES 2096843 T3 ES2096843 T3 ES 2096843T3 ES 93120057 T ES93120057 T ES 93120057T ES 93120057 T ES93120057 T ES 93120057T ES 2096843 T3 ES2096843 T3 ES 2096843T3
Authority
ES
Spain
Prior art keywords
reductose
piridines
hmg
coa
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93120057T
Other languages
English (en)
Inventor
Rolf Dr Angerbauer
Peter Dr Fey
Walter Dr Hubsch
Thomas Dr Philipps
Hilmar Dr Bischoff
Hans-Peter Dr Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2096843T3 publication Critical patent/ES2096843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

NUEVAS PIRIDONAS SUSTITUIDAS SE PRODUCEN AL REDUCIR LOS CORRESPONDIENTES DERIVADOS DE PIRIDINA SUBSTITUIDAS. LAS NUEVAS PIRIDINAS SUBSTITUIDAS SON APROPIADAS COMO SUSTANCIAS ACTIVAS EN MEDICAMENTOS PARTICULARMENTE PARA EL TRATAMIENTO DE HIPERLIPOPROTEINEMIA.
ES93120057T 1992-12-24 1993-12-13 Piridinas sustituidas como inhibidores de reductosa hmg-coa. Expired - Lifetime ES2096843T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4244029A DE4244029A1 (de) 1992-12-24 1992-12-24 Neue substituierte Pyridine

Publications (1)

Publication Number Publication Date
ES2096843T3 true ES2096843T3 (es) 1997-03-16

Family

ID=6476507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93120057T Expired - Lifetime ES2096843T3 (es) 1992-12-24 1993-12-13 Piridinas sustituidas como inhibidores de reductosa hmg-coa.

Country Status (7)

Country Link
US (1) US5409910A (es)
EP (1) EP0603699B1 (es)
JP (1) JP3391873B2 (es)
AT (1) ATE147741T1 (es)
CA (1) CA2112011C (es)
DE (2) DE4244029A1 (es)
ES (1) ES2096843T3 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627420A1 (de) * 1996-07-08 1998-01-15 Bayer Ag 6-(Hydroxymethyl-ethyl)pyridine
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU535944B2 (en) * 1979-06-15 1984-04-12 Merck & Co., Inc. Hypocholestermic fermentation products from aspergillus
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
ES2082755T3 (es) * 1987-07-10 1996-04-01 Hoechst Ag Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios.
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
DE4023308A1 (de) * 1990-07-21 1992-01-23 Bayer Ag Substituierte pyrido-oxazine
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts

Also Published As

Publication number Publication date
EP0603699B1 (de) 1997-01-15
JP3391873B2 (ja) 2003-03-31
DE59305147D1 (de) 1997-02-27
US5409910A (en) 1995-04-25
CA2112011A1 (en) 1994-06-25
EP0603699A1 (de) 1994-06-29
JPH06234740A (ja) 1994-08-23
ATE147741T1 (de) 1997-02-15
DE4244029A1 (de) 1994-06-30
CA2112011C (en) 2005-07-26

Similar Documents

Publication Publication Date Title
DE59303195D1 (de) Substituierte 4-Phenyl-pyridone und 4-Phenyl-2-alkoxypyridine als HMG-CoA-Reductase-Inhitoren
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
DE60140708D1 (de) Prolinderivative und deren Verwendung als Medikamente
FR2678938B1 (fr) Derives de pyrrolidine, leur preparation et les medicaments les contenant.
FI942074A (fi) nor-sappijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
TR199700213A2 (xx) 2-Aril s�bstit�entli piridinler.
ATE173627T1 (de) Medizinische zusammensetzung
DE69222698D1 (de) 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze
FI92195C (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ES2096843T3 (es) Piridinas sustituidas como inhibidores de reductosa hmg-coa.
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
NO306468B1 (no) Nye fosfolipid-derivater, deres fremstilling, legemiddel inneholdende derivatene og derivatenes anvendelse
NO303825B1 (no) Imidazolyl-substituerte cykloheksanderivater, legemidler inneholdende derivatene, anvendelse av derivatene for fremstilling av legemidler samt mellomprodukter for fremstilling av derivatene
ATE63912T1 (de) 4-oxo-1,3-benzodioxan-derivat.
SE9803277D0 (sv) Novel compounds
ES464595A1 (es) Procedimiento de preparacion de nuevos derivados de fenotia-zina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603699

Country of ref document: ES